Tetanus Toxoid Vaccine Market Research On Size, Growth Trends, Segments, Regions & Competition

The Tetanus Toxoid Vaccine Market Report is Segmented by Vaccine Type (Diphtheria, Tetanus, and Pertussis (DTaP), and More), Age Group (Paediatric (0-16 Yrs), and More), End-User (Hospitals & Trauma Centres, and More), Distribution Channel (Government Procurement, and More) and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Tetanus Toxoid Vaccine Market Size and Share

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Compare market size and growth of Tetanus Toxoid Vaccine Market with other markets in Healthcare Industry

Tetanus Toxoid Vaccine Market Analysis by Mordor Intelligence

The atopic dermatitis market is valued at USD 19.3 billion in 2025 and is set to reach USD 30.4 billion by 2030, expanding at a 9.5% CAGR during the forecast period. Demand momentum stems from national immunization programs, rising preference for combination formulations, expanding adult booster policies and sustained multilateral procurement funding. Combination products—especially Tdap—are expanding fastest at 7.9% CAGR, helped by life-course immunization initiatives. North America leads with a 36% revenue share on the strength of mature reimbursement systems, yet Asia Pacific is the high-growth arena, projected at 7.2% CAGR, as governments scale manufacturing capacity, broaden access and increase public-health budgets. Thermostable technologies are poised to reshape supply chains; Phase 1 trials of a fridge-free Td vaccine began in April 2025 and aim to cut cold-chain wastage by more than half[1]University Hospital Southampton, “World-First Trial Launched for Fridge-Free Vaccine,” uhs.nhs.uk. Supply resilience remains a concern because manufacturer exits—such as MassBiologics ending Td output—have exposed concentrated production nodes. Overall, regulatory moves toward Td rather than standalone TT are re-directing tender volumes and influencing product pipelines.

Key Report Takeaways

  • By vaccine type, DTaP led with 42% of tetanus toxoid vaccine market share in 2024, whereas Tdap is forecast to grow at a 7.9% CAGR through 2030.
  • By age group, the paediatric segment accounted for 85% share of the tetanus toxoid vaccine market size in 2024; the adult cohort is projected to advance at a 6.4% CAGR between 2025-2030.
  • By end user, hospitals and trauma centres commanded 68% of 2024 revenue; public immunization clinics represent the fastest trajectory at 6.9% CAGR to 2030.
  • By geography, North America controlled 36% revenue in 2024, while Asia Pacific is set to expand at a 7.2% CAGR to 2030.

Segment Analysis

By Vaccine Type: Combination Vaccines Driving Market Evolution

DTaP secured 42.0% of tetanus toxoid vaccine market share in 2024 on the back of five-dose paediatric schedules. The tetanus toxoid vaccine market size for this segment is forecast to exhibit mid-single-digit growth as guidelines remain unchanged. Tdap’s 7.9% CAGR outpaces the wider market because adolescent, maternal and adult boosters are scaling; CDC endorses Tdap during every pregnancy, with >90% infant pertussis protection.

Standalone TT products are declining as tenders pivot to Td, and mRNA DTP prototypes could disrupt pricing and manufacturing paradigms by late forecast. The tetanus toxoid vaccine industry therefore concentrates R&D on higher-valent, thermostable or genetic-platform formulations to preserve relevance amid evolving schedules.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Age Group: Adult Segment Gaining Momentum Despite Paediatric Dominance

Paediatrics held 85.0% share of the tetanus toxoid vaccine market size in 2024, sustained by school-entry mandates and VFC entitlements. Nonetheless, adults show a 6.4% CAGR as immunosenescence and injury-prone lifestyles highlight booster gaps. Evidence of disproportionate tetanus cases among seniors with lapsed immunity underscores an unmet need.

Policy levers such as Medicare cost caps remove financial barriers, while rapid saliva testing enables targeted outreach within minutes. These factors collectively reposition the adult cohort as a growth lever in the tetanus toxoid vaccine market.

By End User: Public Immunization Clinics Gaining Ground in Fragmented Landscape

Hospitals and trauma centres generated 68% revenue in 2024 due to their central role in wound management protocols. Their integrated electronic records ensure immediate prophylaxis decisions, anchoring volume density. Yet community clinics, supported by mobile teams and culturally adapted campaigns, will post 6.9% CAGR, reflecting equity-driven funding rounds such as Wisconsin’s RICE grants.

Low-fee schedules—USD 21.23 for Td in San Antonio, USD 40.20 for Tdap—draw price-sensitive users. Expansion of pharmacy and workplace channels widens convenience, steering incremental syringes to the tetanus toxoid vaccine market.

Tetanus Toxoid Vaccine Market
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Distribution Channel: Government Procurement Dominates While Private Sector Expands

National tendering under EPI, NEPI or similar constructs anchors aggregate demand and shapes technical specs. Vietnam’s public programme supplies Td free-of-charge, with pricing set centrally. UNICEF alone met 40% of global Td volumes in 2022, illustrating the heft of institutional buyers.

The private/self-pay channel is rising because insurers must cover ACIP-listed vaccines in-network at zero cost-share as of October 2023. Upgraded regional distribution centres promise scale economies that reduce landed costs and curtail wastage. Competitive tenders and private adoption together expand accessibility, growing the tetanus toxoid vaccine market.

Geography Analysis

North America delivered 36.0% of 2024 revenue, supported by mature coverage systems and the Inflation Reduction Act’s zero cost-share adult vaccine clause. Nonetheless, the 2024 Td shortfall revealed vulnerabilities and forced clinics to substitute with Tdap in certain settings. California has intensified Tdap outreach amid pertussis spikes, especially targeting pregnancies week 27-36. Sustained legislative and funding support maintain the region’s central role in the tetanus toxoid vaccine market.

Asia Pacific stands out with a 7.2% CAGR to 2030. India supplies 60% of vaccines for global immunisation programmes, while China covers 90% of its domestic need. Government incentives and WHO prequalification pathways bolster exports. Vietnam’s private vaccine turnover above USD 300 million underscores rising middle-class demand. Regional capacity—Serum Institute’s 3 billion doses and Bharat Biotech’s 4 billion—supports scalable supply, underscoring the region’s next-wave influence on the tetanus toxoid vaccine market.

Europe, the Middle East, Africa and South America exhibit heterogeneous drivers. Europe maintains high coverage but confronts pockets of hesitancy. Forty-seven of 59 high-risk nations have now eliminated maternal and neonatal tetanus, many in Africa, reflecting successful donor-backed drives. AVMA’s USD 1 billion initiative seeks to lift Africa’s share of global output beyond today’s 0.2%. PAHO bulk-procurement models stabilise South American pricing. Collectively these regions broaden geographic diversity and mitigate concentration risks within the tetanus toxoid vaccine market.

Tetanus Toxoid Vaccine Market
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

Global supply is moderately concentrated among Sanofi, GSK, Pfizer, Merck and Serum Institute of India. The latter lifted its share to 24% by 2023, benefiting from cost competitiveness and prequalification wins. Emerging Asian firms such as CanSino, Bharat Biotech and multiple Chinese biologics manufacturers are scaling capabilities, especially in combination and adult-dose formulations, increasing rivalry inside the tetanus toxoid vaccine market.

Strategic themes include thermostable R&D—Stablepharma’s SPVX02 could up-end cold-chain economics —and monoclonal antitoxin therapies such as Trinomab’s Sintetol, which offers rapid antibody delivery for post-exposure management. Regulatory environments are diverging; compliance agility therefore becomes a competitive differentiator. Price pressure persists as pooled tenders weigh suppliers against one another, yet differentiation through platform science and adult-specific dossiers promises margin defence. White-space exists in Africa-based manufacturing where local players may leverage AVMA grants to secure regional tenders, slowly diluting import dependence in the tetanus toxoid vaccine market.

Post-2027, mRNA combination candidates could redefine barriers to entry by compressing lead times and enabling flexible antigen swaps, causing incumbent toxoid producers to invest in new platform capabilities. Consolidation risk remains if smaller suppliers cannot fund next-generation upgrades, possibly raising the tetanus toxoid vaccine industry’s concentration over the long term.

Tetanus Toxoid Vaccine Industry Leaders

  1. Sanofi (Sanofi Pasteur, Inc)

  2. Pfizer, Inc

  3. GSK plc

  4. Serum Institute of India Pvt. Ltd.

  5. Merck & Co., Inc.

  6. *Disclaimer: Major Players sorted in no particular order
Tetanus Toxoid Vaccine Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • March 2025: Trinomab launched Sintetol, a recombinant anti-tetanus monoclonal antibody delivering protective titres in 12 hours for 95.4% of patients.
  • May 2025: CanSino reported 137% 2024 revenue growth, propelled by DTcP programme advancements.
  • February 2025: Trinomab Biotech secured Chinese approval for Siltartoxatug, an anti-toxin mAb with multiple expedited designations.
  • February 2025: CanSino’s DTcP-Hib-MCV4 combined vaccine entered clinical trials; Tdcp for ages 6+ reached Phase II/III.

Table of Contents for Tetanus Toxoid Vaccine Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Expansion of National Immunisation Programmes & Booster Policy Updates
    • 4.2.2 Growing Adoption of Pentavalent & Hexavalent Combination Vaccines
    • 4.2.3 Sustained Procurement Funding from UNICEF, Gavi & PAHO Revolving Fund
    • 4.2.4 Rising Awareness of Adult Booster Immunisation in Developed & Emerging Markets
    • 4.2.5 Entry of Cost-competitive Manufacturers via WHO Prequalification Pathway
    • 4.2.6 Advancements in Low-dose Adjuvant & Thermostable Formulation Technologies
  • 4.3 Market Restraints
    • 4.3.1 Vaccine Hesitancy & Misinformation Undermining Uptake Across All Age Groups
    • 4.3.2 Concentrated Manufacturing Base Creating Supply-chain Vulnerability
    • 4.3.3 Budgetary Constraints for Td/Tdap Transition in Low- & Middle-Income Countries
    • 4.3.4 Adverse Events & Litigation Risks Linked to Combination Vaccines
  • 4.4 Regulatory Outlook
  • 4.5 Porter's Five Forces Analysis
    • 4.5.1 Threat of New Entrants
    • 4.5.2 Bargaining Power of Buyers (UNICEF, PAHO Revolving Fund)
    • 4.5.3 Bargaining Power of Suppliers
    • 4.5.4 Threat of Substitutes (Hyper-immune Globulin, mRNA)
    • 4.5.5 Intensity of Competitive Rivalry

5. Market Size & Growth Forecasts (Value, USD)

  • 5.1 By Vaccine Type
    • 5.1.1 Diphtheria, Tetanus, and Pertussis (DTaP)
    • 5.1.2 Diphtheria and Tetanus (DT)
    • 5.1.3 Tetanus, Diphtheria, And Pertussis (Tdap)
    • 5.1.4 Other Vaccine Types
  • 5.2 By Age Group
    • 5.2.1 Paediatric (0-16 yrs)
    • 5.2.2 Adult (>16 yrs)
  • 5.3 By End User
    • 5.3.1 Hospitals & Trauma Centres
    • 5.3.2 Public Immunisation Clinics & EPI Sites
    • 5.3.3 Other End Users
  • 5.4 By Distribution Channel
    • 5.4.1 Government Procurement
    • 5.4.2 Private / Self-pay
  • 5.5 Geography
    • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
    • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 South Korea
    • 5.5.3.5 Australia
    • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle-East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
    • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Strategic Moves
  • 6.3 Market Share Analysis
  • 6.4 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
    • 6.4.1 Sanofi (Sanofi Pasteur)
    • 6.4.2 GSK plc
    • 6.4.3 Pfizer Inc.
    • 6.4.4 Merck & Co., Inc.
    • 6.4.5 Serum Institute of India Pvt. Ltd.
    • 6.4.6 Bharat Biotech International Ltd.
    • 6.4.7 Biological E Ltd.
    • 6.4.8 Panacea Biotec Ltd.
    • 6.4.9 BB-NCIPD Ltd.
    • 6.4.10 PT Bio Farma (Persero)
    • 6.4.11 Emergent BioSolutions Inc.
    • 6.4.12 LG Chem Ltd.
    • 6.4.13 Sinopharm Group Co., Ltd.
    • 6.4.14 Sinovac Biotech Ltd.
    • 6.4.15 KM Biologics (Mitsubishi Tanabe)
    • 6.4.16 Seqirus (CSL Ltd.)
    • 6.4.17 Aurobindo Pharma Ltd. (Vaccines Div.)
    • 6.4.18 Valneva SE

7. Market Opportunities & Future Outlook

  • 7.1 White-space & Unmet-need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Tetanus Toxoid Vaccine Market Report Scope

As per the scope of the report, the tetanus vaccine, also known as tetanus toxoid, is a toxoid vaccine used to prevent tetanus. Five doses are recommended during childhood, with a sixth given during adolescence. After three doses, almost everyone is initially immune, but additional doses every 10 years are recommended to maintain immunity.

The tetanus toxoid vaccine market is segmented by vaccine type, end user, and geography. By vaccine type, the market is segmented into diphtheria, tetanus, and pertussis (DTaP), diphtheria and tetanus (DT), tetanus, diphtheria, and pertussis (Tdap), and other vaccines. By end user, the market is segmented into hospitals and clinics and other end users. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. For each segment, the market size is provided in terms of USD value.

By Vaccine Type Diphtheria, Tetanus, and Pertussis (DTaP)
Diphtheria and Tetanus (DT)
Tetanus, Diphtheria, And Pertussis (Tdap)
Other Vaccine Types
By Age Group Paediatric (0-16 yrs)
Adult (>16 yrs)
By End User Hospitals & Trauma Centres
Public Immunisation Clinics & EPI Sites
Other End Users
By Distribution Channel Government Procurement
Private / Self-pay
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
South Korea
Australia
Rest of Asia-Pacific
Middle-East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
By Vaccine Type
Diphtheria, Tetanus, and Pertussis (DTaP)
Diphtheria and Tetanus (DT)
Tetanus, Diphtheria, And Pertussis (Tdap)
Other Vaccine Types
By Age Group
Paediatric (0-16 yrs)
Adult (>16 yrs)
By End User
Hospitals & Trauma Centres
Public Immunisation Clinics & EPI Sites
Other End Users
By Distribution Channel
Government Procurement
Private / Self-pay
Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
South Korea
Australia
Rest of Asia-Pacific
Middle-East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

What is the current size of the tetanus toxoid vaccine market?

The tetanus toxoid vaccine market is valued at USD 6.13 billion in 2025 and is projected to reach USD 8.08 billion by 2030.

Which vaccine segment is growing fastest?

The Tdap segment posts the strongest momentum with a 7.9% CAGR through 2030, driven by adolescent, maternal and adult booster recommendations.

Why is Asia Pacific considered the high-growth region?

Asia Pacific combines expanding immunization programmes, large-scale manufacturing capacity in India and China and rising private-sector demand, leading to a 7.2% CAGR forecast.

How will thermostable technology affect the market?

Thermostable formulations like Stablepharma’s SPVX02 aim to eliminate cold-chain dependence, potentially cutting wastage and broadening reach in remote areas, thereby unlocking new demand pockets.

What are the main risks to supply continuity?

The manufacturing base remains concentrated; recent exits such as MassBiologics have caused regional shortages, and any similar disruptions can impact global availability until more suppliers gain WHO prequalification.

Are adult booster campaigns making a difference?

Yes. Adult uptake still lags paediatrics, but booster awareness, Medicare cost caps and rapid immunity tests are propelling a 6.4% CAGR in the adult segment, signalling a growing life-course market opportunity.

Tetanus Toxoid Vaccine Market Report Snapshots